Literature DB >> 24350845

Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

I A Schepetkin, A I Khlebnikov, M P Giovannoni, L N Kirpotina, A Cilibrizzi, M T Quinn1.   

Abstract

Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure-activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24350845      PMCID: PMC6791360          DOI: 10.2174/0929867321666131218095521

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  170 in total

1.  Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2010-09-15       Impact factor: 6.514

Review 2.  Receptor-based pharmacophore and pharmacophore key descriptors for virtual screening and QSAR modeling.

Authors:  Xialan Dong; Jerry O Ebalunode; Sheng-Yong Yang; Weifan Zheng
Journal:  Curr Comput Aided Drug Des       Date:  2011-09-01       Impact factor: 1.606

Review 3.  Computational drug discovery.

Authors:  Si-Sheng Ou-Yang; Jun-Yan Lu; Xiang-Qian Kong; Zhong-Jie Liang; Cheng Luo; Hualiang Jiang
Journal:  Acta Pharmacol Sin       Date:  2012-08-27       Impact factor: 6.150

4.  The agonists of formyl peptide receptors prevent development of severe sepsis after microbial infection.

Authors:  Sang Doo Kim; Yoon-Keun Kim; Ha Young Lee; You-Sun Kim; Seong Gyu Jeon; Suk-Hwan Baek; Dong-Keun Song; Sung Ho Ryu; Yoe-Sik Bae
Journal:  J Immunol       Date:  2010-09-03       Impact factor: 5.422

5.  T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor.

Authors:  S B Su; W H Gong; J L Gao; W P Shen; M C Grimm; X Deng; P M Murphy; J J Oppenheim; J M Wang
Journal:  Blood       Date:  1999-06-01       Impact factor: 22.113

6.  Characterization of two new members of the formyl peptide receptor gene family from 129S6 mice.

Authors:  Zhen-Guo Wang; Richard D Ye
Journal:  Gene       Date:  2002-10-16       Impact factor: 3.688

7.  Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Authors:  Liliya N Kirpotina; Andrei I Khlebnikov; Igor A Schepetkin; Richard D Ye; Marie-Josèphe Rabiet; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2009-11-10       Impact factor: 4.436

8.  Signal transducing properties of the N-formyl peptide receptor expressed in undifferentiated HL60 cells.

Authors:  E R Prossnitz; O Quehenberger; C G Cochrane; R D Ye
Journal:  J Immunol       Date:  1993-11-15       Impact factor: 5.422

9.  Receptor-directed inhibition of chemotactic factor-induced neutrophil hyperactivity by pyrazolon derivatives. Definition of a chemotactic peptide antagonist.

Authors:  C Dahinden; J Fehr
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

10.  Structure and function of an irreversible agonist-β(2) adrenoceptor complex.

Authors:  Daniel M Rosenbaum; Cheng Zhang; Joseph A Lyons; Ralph Holl; David Aragao; Daniel H Arlow; Søren G F Rasmussen; Hee-Jung Choi; Brian T Devree; Roger K Sunahara; Pil Seok Chae; Samuel H Gellman; Ron O Dror; David E Shaw; William I Weis; Martin Caffrey; Peter Gmeiner; Brian K Kobilka
Journal:  Nature       Date:  2011-01-13       Impact factor: 49.962

View more
  25 in total

1.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

2.  4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Authors:  Liliya N Kirpotina; Igor A Schepetkin; Andrei I Khlebnikov; Olga I Ruban; Yunjun Ge; Richard D Ye; Douglas J Kominsky; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2017-07-08       Impact factor: 5.858

3.  Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Richard D Ye; Mark T Quinn
Journal:  Drug Dev Res       Date:  2016-11-18       Impact factor: 4.360

4.  Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.

Authors:  Madia L Stama; Enza Lacivita; Liliya N Kirpotina; Mauro Niso; Roberto Perrone; Igor A Schepetkin; Mark T Quinn; Marcello Leopoldo
Journal:  ChemMedChem       Date:  2017-11-07       Impact factor: 3.466

5.  Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.

Authors:  Enza Lacivita; Igor A Schepetkin; Madia L Stama; Liliya N Kirpotina; Nicola A Colabufo; Roberto Perrone; Andrei I Khlebnikov; Mark T Quinn; Marcello Leopoldo
Journal:  Bioorg Med Chem       Date:  2014-12-13       Impact factor: 3.641

Review 6.  Antagonism of human formyl peptide receptor 1 with natural compounds and their synthetic derivatives.

Authors:  Igor A Schepetkin; Andrei I Khlebnikov; Liliya N Kirpotina; Mark T Quinn
Journal:  Int Immunopharmacol       Date:  2015-09-15       Impact factor: 4.932

7.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

8.  FAM19A4 is a novel cytokine ligand of formyl peptide receptor 1 (FPR1) and is able to promote the migration and phagocytosis of macrophages.

Authors:  Wenyan Wang; Ting Li; Xiaolin Wang; Wanxiong Yuan; Yingying Cheng; Heyu Zhang; Enquan Xu; Yingmei Zhang; Shuang Shi; Dalong Ma; Wenling Han
Journal:  Cell Mol Immunol       Date:  2014-08-11       Impact factor: 11.530

9.  Aurantiamide-related dipeptide derivatives are formyl peptide receptor 1 antagonists.

Authors:  Margherita Mastromarino; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Enza Lacivita; Marcello Leopoldo
Journal:  Medchemcomm       Date:  2019-10-07       Impact factor: 3.597

Review 10.  The role of formylated peptides and formyl peptide receptor 1 in governing neutrophil function during acute inflammation.

Authors:  David A Dorward; Christopher D Lucas; Gavin B Chapman; Christopher Haslett; Kevin Dhaliwal; Adriano G Rossi
Journal:  Am J Pathol       Date:  2015-03-17       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.